Sun Pharma Advanced Research Company (SPARC) reported unaudited results for the first quarter ended June 30, 2011.
The company posted a net loss of Rs 11.26 crore for the first quarter ended June 30, 2011 against net profit of Rs 48 lakh in the same period previous fiscal. The company's total income declined by 31.57% at Rs 10.08 crore in the June quarter, while the same was Rs 14.73 crore in the corresponding period of last financial year.
SPARC is engaged in the pharmaceutical research and development. The company’s core focus is innovation and new product development for global markets. SPARC undertakes projects in research and technology for new chemical entities (NCE’s) or new molecules, and novel drug delivery systems (NDDS).
